A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The primary objectives of this study are to evaluate the clinical safety and tolerability and to assess the efficacy of 100 mg, 200 mg, and 300 mg BID dextofisopam compared with placebo in female outpatients with diarrhea-predominant or alternating irritable bowel syndrome (IBS).
Epistemonikos ID: 8d91d85b71c9420fe35271f57e40baee5ff52057
First added on: May 04, 2024